Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Bucillamine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Revive Updates R&D Focus on Bucillamine for Infectious Diseases
    Revive Updates R&D Focus on Bucillamine for Infectious Diseases

    03 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2025/02/03/3019905/0/en/Revive-Therapeutics-Announces-Update-on-R-D-Focus-on-Bucillamine-for-Infectious-Diseases-and-Medical-Countermeasures.html

    GLOBENEWSWIRE
    03 Feb 2025
    Share Share
    Revive Updates Bucillamine Study For Nerve Agent Exposure Research
    Revive Updates Bucillamine Study For Nerve Agent Exposure Research

    08 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/08/3006148/0/en/Revive-Therapeutics-Provides-Update-on-Research-Study-Evaluating-Bucillamine-for-Nerve-Agent-Exposure.html

    GLOBENEWSWIRE
    08 Jan 2025
    Share Share
    Revive Therapeutics Provides Bucillamine Nerve Agent Study Update
    Revive Therapeutics Provides Bucillamine Nerve Agent Study Update

    31 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/31/2972503/0/en/Revive-Therapeutics-Provides-Update-on-Research-Study-Evaluating-Bucillamine-for-Nerve-Agent-Exposure.html

    GLOBENEWSWIRE
    31 Oct 2024
    Share Share
    Revive Focuses On Bucillamine For Infectious Diseases
    Revive Focuses On Bucillamine For Infectious Diseases

    18 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/18/2948084/0/en/Revive-Therapeutics-Announces-Strategic-Focus-on-Bucillamine-for-Infectious-Diseases-and-Medical-Countermeasures.html

    GLOBENEWSWIRE
    18 Sep 2024
    Share Share
    Revive Therapeutics Updates On Bucillamine Research For Nerve Agents
    Revive Therapeutics Updates On Bucillamine Research For Nerve Agents

    28 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/28/2936877/0/en/Revive-Therapeutics-Provides-Update-on-Research-Study-Evaluating-Bucillamine-for-Nerve-Agent-Exposure-and-Expansion-into-Viral-Infections.html

    GLOBENEWSWIRE
    28 Aug 2024
    Share Share
    Revive Therapeutics Updates On Bucillamine For Nerve Agent Exposure Study
    Revive Therapeutics Updates On Bucillamine For Nerve Agent Exposure Study

    02 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/02/2907735/0/en/Revive-Therapeutics-Provides-Update-on-Research-Study-Evaluating-Bucillamine-for-Nerve-Agent-Exposure.html

    GLOBENEWSWIRE
    02 Jul 2024
    Share Share